Centessa Pharmaceuticals’ (CNTA) “Buy” Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note issued to investors on Monday,Benzinga reports.

Separately, TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Trading Up 4.3 %

Centessa Pharmaceuticals stock opened at $18.00 on Monday. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09. The stock has a market capitalization of $2.37 billion, a PE ratio of -11.76 and a beta of 1.53. The firm has a 50 day simple moving average of $16.80 and a 200-day simple moving average of $15.56. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. The trade was a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total value of $928,950.00. Following the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $9,722,914.29. The trade was a 8.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 452,652 shares of company stock valued at $7,800,532. 11.59% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of large investors have recently made changes to their positions in CNTA. GAMMA Investing LLC grew its position in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $259,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after acquiring an additional 6,785 shares in the last quarter. Finally, Atria Investments Inc boosted its position in Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.